VRTX Stock Recent News

A new month has arrived. Investors now have a fresh opportunity to buy great stocks.

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising macroeconomic uncertainties, and geopolitical challenges, have weighed on overall investor sentiment.

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the uncertain near-term economic outlook. Even with these issues, though, stocks are likely to produce superior returns to most other assets over the next decade, as they have consistently done in the past.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Call Participants Will Pickering - Bernstein Will Pickering All right. Well, I think we can get started.

Believe it or not, but we're not far away from being halfway through the year. Time flies when you're having fun -- and when you're not having fun, too.

The market's recent correction looks like a massive drop on a year-to-date chart. However, it will look far less daunting in a decade; that's what happens over the long run.

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues. VRTX valuation is justified by stable CF cash flows, a strong balance sheet, proven management, and a diversified pipeline with multiple near-term catalysts.

Resilient and growing. Those two descriptions definitely apply to the healthcare sector.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions.

The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.